ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Abstracts tagged "certolizumab pegol and psoriatic arthritis"

  • Abstract Number: 2860 • ACR/ARHP Annual Meeting 2015

    Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol

    Arthur Kavanaugh1, Dafna Gladman2, Désirée van der Heijde3, Oana Purcaru4 and Philip J. Mease5, 1University of California San Diego, La Jolla, CA, 2University of Toronto, Toronto, ON, Canada, 3Leiden University Medical Center, Leiden, Netherlands, 4UCB Pharma, Brussels, Belgium, 5Rheumatology Research, Swedish Medical Center, Seattle, WA

    Background/Purpose: Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 Few studies have…
  • Abstract Number: 2613 • ACR/ARHP Annual Meeting 2012

    Effect of Certolizumab Pegol On Signs and Symptoms in Patients with Psoriatic Arthritis with and without Prior Anti-TNF Exposure: 24 Week Results of a Phase 3 Double-Blind Randomized Placebo-Controlled Study

    Philip J. Mease1, Roy Fleischmann2, Jürgen Wollenhaupt3, Atul A. Deodhar4, Danuta Kielar5, Franz Woltering6, Christian Stach6, Bengt Hoepken6, Terri Arledge7 and Désirée van der Heijde8, 1Seattle Rheumatology Associates, Seattle, WA, 2University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 3Schön-Klinik, Hamburg, Germany, 4Oregon Health & Science University, Portland, OR, 5UCB Pharma, Brussels, Belgium, 6UCB Pharma, Monheim am Rheim, Germany, 7UCB Pharma, Rtp, NC, 8Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, has shown efficacy in reducing signs and symptoms of psoriatic arthritis (PsA).1 RAPID-PsA (NCT01087788) is the first…

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology